Public Employees Retirement System of Ohio lifted its position in shares of STERIS plc (NYSE:STE - Free Report) by 16.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,928 shares of the medical equipment provider's stock after purchasing an additional 6,345 shares during the quarter. Public Employees Retirement System of Ohio's holdings in STERIS were worth $10,654,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in STE. Massachusetts Financial Services Co. MA grew its stake in STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider's stock valued at $1,414,453,000 after acquiring an additional 778,613 shares during the period. Impax Asset Management Group plc grew its position in shares of STERIS by 29.7% in the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider's stock valued at $251,663,000 after purchasing an additional 263,383 shares during the period. Principal Financial Group Inc. increased its stake in STERIS by 9.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider's stock worth $270,230,000 after purchasing an additional 96,336 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in STERIS by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 840,194 shares of the medical equipment provider's stock worth $184,439,000 after buying an additional 95,412 shares during the period. Finally, Raymond James & Associates lifted its stake in STERIS by 1.5% in the third quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider's stock valued at $194,309,000 after buying an additional 12,005 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.
STERIS Stock Performance
Shares of STERIS stock traded up $6.74 during trading on Thursday, hitting $216.36. 690,405 shares of the stock were exchanged, compared to its average volume of 500,540. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average price of $221.14 and a 200-day moving average price of $227.35. The stock has a market capitalization of $21.36 billion, a price-to-earnings ratio of 49.40 and a beta of 0.83. STERIS plc has a 1-year low of $197.82 and a 1-year high of $248.24.
STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts' consensus estimates of $2.12 by $0.02. The firm had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business's revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.03 earnings per share. As a group, equities analysts predict that STERIS plc will post 9.1 EPS for the current fiscal year.
STERIS Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 1.05%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio is 52.05%.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on STE shares. Piper Sandler raised shares of STERIS from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research report on Friday, November 8th. Stephens restated an "overweight" rating and set a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. StockNews.com lowered STERIS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, October 29th. Finally, JMP Securities restated a "market outperform" rating and issued a $265.00 price target on shares of STERIS in a research note on Monday, November 18th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $262.50.
Get Our Latest Stock Report on STE
Insider Buying and Selling at STERIS
In related news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares of the company's stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.14% of the company's stock.
STERIS Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Stories
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.